33% revenue growth masks margin dilution; expansion execution risk

₹470 Cr reported, +33.2% YoY confirmed; organic +24%, acquisitions +₹38 Cr

EBITDA ₹134.6 Cr, 28.6% margin confirmed despite new hospital losses

₹62.5 Cr PAT, +16.2% YoY; BUT QoQ down 20% despite 2.2% revenue QoQ

Q2 FY27 explicitly guided for 20% growth; medium-term target 20% to double revenue in 4 yrs

Guidance confirmed; margins currently 28.6%, but acknowledged expansion-driven pressure

Rajahmundry breakeven confirmed; Electronic City expected breakeven 2–3 months. Bengaluru units still in investment phase with losses. Mixed validation.

FY26 target (20% revenue growth) reaffirmed for medium term. No change, but execution in Q1 shows topline achieved (33%), profitability lagged.

Long-term 24–25% target restated; current 28.6% acknowledged as temporarily elevated due to new hospital losses. Implies margins will moderate, not improve further.

Management separated organic (+24%) from reported (+33%), highlighting ₹38 Cr acquisition contribution. Organic growth moderating vs prior perception of pure organic expansion.

Rajahmundry breakeven achieved; Electronic City, HRBR 12–15 month target reconfirmed, not accelerated. Timeline tracking, not beating.

Visibility on 1,200 beds under development. Actively evaluating Noida, Central India, Bhubaneswar, Raipur. Hub-and-spoke model in all markets, no single-hospital isolation.

Actively evaluating government reimbursement in new markets with excess beds. Decision dependent on rates and clinical sustainability, not opportunistic.

Revenue target: ₹2,000 Cr FY27, double over 4 years (20% CAGR). ARPOB mature ₹70K, new <5yr ₹59K (18% gap). Sustainable 5–6% ARPOB CAGR.

Mumbai EBITDA >20% expected eventually, too early for precision. Full-time doctor model preferred. Digital transformation 3–4 months, foundational done. Long-term margin guidance 24–25%.

Bandwidth improved significantly. Cluster Heads oversee 2–4 hospitals. Regional structures being built for Delhi NCR, Mumbai. Execution proven.

Cost management priority: integrating acquisitions, optimizing greenfield. Treasury balancing liquidity, safety, yields. Project execution and capex management ongoing priorities.

Hardest element: assembling high-quality medical teams + earning community trust. Seasonality always factor, but objective to make seasonal demand supplementary, not key driver.

Acquisitions ₹38 Cr revenue; organic growth 24% like-to-like. ARPOB up due to pricing + case mix. Bengaluru units 12–15 month breakeven target; no quantified loss.

Yes, would like large hub hospital in Mumbai. Current priority: integrate Malad before pursuing next expansion phase.

Too early for seasonality (July). Malad: unmet need for high-acuity pediatric care in 8M population radius. Nellore/Guntur not expected to drag EBITDA.

Explicitly stated twice; aligned with FY26 prior guidance. Base higher but execution proven.

Grounded in visibility of 1,200 beds under development + organic trajectory + acquisition pipeline. Forward-looking.

1,200 beds visible; remaining 1,300 beds subject to M&A/real estate execution risk in new geographies.

Reaffirmed multiple times. Implies margin compression from current 28.6% as new hospitals ramp and integration costs persist. Long-term guidance, not expansion.

Hedged guidance. Higher cost structure (labor, doctor fees) in Mumbai; pricing power acknowledged but unproven at scale.

Vague aspiration. New hospital drag quantified as temporary; no specific quarterly margin targets beyond year-end recovery.

Specific number; internally funded via accruals + strong cash generation. No external debt planned.

Blend of greenfield + acquisition minimizes capex intensity. Strategy shifting toward asset-light leases (Guntur 50-bed lease).

Scaling to 5+ new metros (Mumbai, Delhi NCR, Indore, Pune, Guwahati, Bhubaneswar) simultaneously. Building clinical teams, earning trust, managing integration—historically hardest element per CEO.

Bengaluru units (HRBR, Electronic City), Rajahmundry just at breakeven. Q1 EBITDA drag from new hospitals acknowledged. 12–15 month breakeven guidance could slip; if delayed, FY27 margin recovery to 24–25% at risk.

First Western India entry. Higher cost structure (labor, doctor salary). EBITDA margin >20% targeted but 'too early to estimate' where it stabilizes. Multi-specialty competitors entrenched. Malad location (West suburbs) limits immediate premium-market capture.

Q1 showed 16% PAT growth vs 33% revenue; QoQ PAT fell 20%. Margin guidance explicitly ratcheted to 24–25% (vs current 28.6%), implying compression from current levels. If ramp losses persist, recovery delayed and FY27 guidance missed.

Q2–Q3 normally strong. Monsoon deficit noted for FY27; management hedging, saying seasonal demand should be 'supplementary' not 'key driver.' Structural shift to non-seasonal revenue not yet proven.